Physician profile
Samir Shah
NPI 1447434469
$1,447.46
in general payments reported to CMS, 2019-2025
17 companies · $356 in 2025
The $356 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $459 · 2020: $13.42 · 2021: $107 · 2022: $242 · 2023: $134 · 2024: $136 · 2025: $356.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $626.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $626.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shockwave Medical, INC | $298.97 | 2025 | |
| Novartis Pharmaceuticals Corporation | $188.88 | 2019-2025 | |
| Boston Scientific Corporation | $185.35 | 2019-2023 | Watchman Flx, Watchman Access System |
| Abiomed | $135.77 | 2024 | Impella |
| Janssen Pharmaceuticals, INC | $109.90 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $108.08 | 2021-2023 | Verquvo |
| Amgen INC. | $90.07 | 2019-2025 | Repatha |
| Astrazeneca Pharmaceuticals LP | $81.39 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $67.30 | 2019-2022 | |
| Amarin Pharma, INC. | $35.29 | 2019 | |
| Gilead Sciences, INC. | $30.68 | 2019 | |
| Sanofi-Aventis U.S. LLC | $28.92 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $25.00 | 2019 | |
| Heartflow, INC. | $22.05 | 2025 | |
| Arbor Pharmaceuticals, INC. | $14.52 | 2019 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $13.86 | 2021 | |
| Pfizer INC. | $11.43 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samir Shah listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.